{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:07:56Z","timestamp":1788782876028,"version":"build-2803163510"},"reference-count":37,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/na","name":"Alfred D. and Audrey M. Petersen Professorship and James C. and Sarah K. Kennedy Deanship","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Norwegian Cancer Society","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The use of natural killer (NK) cells for the treatment of solid tumors such as cholangiocarcinoma has been hindered by challenges related to cell production, persistence and trafficking, as well as by reduced efficacy within an immunosuppressive tumor microenvironment. Antitumor immunity can be reduced by the interaction of NK cell expressed programmed cell death protein 1 (PD1) with ligands on tumor and other cells within the tumor microenvironment. The antitumor effect of NK cells is enhanced in cells engineered to express a truncated PD1 without an intracellular domain. The cytolytic potential and therapeutic efficacy of extracellular vesicles (EVs) derived from human NK cells expressing truncated PD1 was evaluated as a cell-free therapeutic to overcome some limitations faced by cell therapies. We demonstrate the feasibility of efficient expansion, production and isolation of therapeutic vesicles from human NK cell lines and from engineered NK92 cells expressing truncated PD1. The cytotoxic efficacy of these therapeutic vesicles was validated in both monolayer tumor cell cultures and in multicellular tumor spheroids. Concomitant administration of gemcitabine upregulated NKG2D ligands on tumor cells and increased susceptibility to NK cell and to NK cell derived EV mediated killing. These findings position engineered NK cell derived-EVs as a scalable and promising cell-free immunotherapeutic for cholangiocarcinoma.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00219","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:02:08Z","timestamp":1787000528000},"page":"4540-4552","source":"Crossref","is-referenced-by-count":0,"title":["Engineered\nNatural Killer Cell Derived-Extracellular\nVesicles: An Acellular Immunotherapy with Cytotoxic Effects in SNU-1079\nHuman Cholangiocarcinoma Cells"],"prefix":"10.1021","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-5785","authenticated-orcid":true,"given":"Piyush","family":"Gondaliya","sequence":"first","affiliation":[{"name":"Mayo Clinic , , , ,","place":["Jacksonville, Florida, United States, 32224"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1634-2465","authenticated-orcid":true,"given":"Dylan A.","family":"Zinn","sequence":"additional","affiliation":[{"name":"Mayo Clinic , , , ,","place":["Jacksonville, Florida, United States, 32224"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5860-7890","authenticated-orcid":true,"given":"Adil Ali","family":"Sayyed","sequence":"additional","affiliation":[{"name":"Mayo Clinic , , , ,","place":["Jacksonville, Florida, United States, 32224"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Driscoll","sequence":"additional","affiliation":[{"name":"Mayo Clinic , , , ,","place":["Jacksonville, Florida, United States, 32224"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene K.","family":"Yan","sequence":"additional","affiliation":[{"name":"Mayo Clinic , , , ,","place":["Jacksonville, Florida, United States, 32224"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Mensali","sequence":"additional","affiliation":[{"name":"Oslo University Hospital , , ,","place":["Oslo, Norway, 0379"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u0301bastien","family":"Wa\u0308lchli","sequence":"additional","affiliation":[{"name":"Oslo University Hospital , , ,","place":["Oslo, Norway, 0379"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-9532","authenticated-orcid":true,"given":"Tushar","family":"Patel","sequence":"additional","affiliation":[{"name":"Mayo Clinic , , , ,","place":["Jacksonville, Florida, United States, 32224"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"2026090707082841500_cit1","doi-asserted-by":"publisher","first-page":"1595533","DOI":"10.3389\/fimmu.2025.1595533","article-title":"Recent advances\nin tumor immunotherapy based on NK cells","volume":"16","author":"Chen","year":"2025","journal-title":"Front.\nImmunol."},{"issue":"2","key":"2026090707082841500_cit2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cas.12853","article-title":"Overexpression\nof natural killer group 2 member D ligands\npredicts favorable prognosis in cholangiocarcinoma","volume":"107","author":"Tsukagoshi","year":"2016","journal-title":"Cancer Sci."},{"issue":"1","key":"2026090707082841500_cit3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/hep.21964","article-title":"Cholangiocarcinoma\nin primary sclerosing cholangitis is associated with NKG2D polymorphisms","volume":"47","author":"Melum","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"2026090707082841500_cit4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jhepr.2019.06.003","article-title":"Immunobiology of\ncholangiocarcinoma","volume":"1","author":"Loeuillard","year":"2019","journal-title":"JHEP Rep"},{"key":"2026090707082841500_cit5","doi-asserted-by":"publisher","first-page":"1303605","DOI":"10.3389\/fimmu.2023.1303605","article-title":"NK cell exhaustion\nin the tumor microenvironment","volume":"14","author":"Jia","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"2026090707082841500_cit6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41467-024-44789-z","article-title":"Rapid functional impairment\nof natural killer\ncells following tumor entry limits anti-tumor immunity","volume":"15","author":"Dean","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"2026090707082841500_cit7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1158\/1541-7786.MCR-24-0299","article-title":"Intra- and Extrahepatic\nCholangiocarcinomas Display\nDiffering Sensitivities to NK Cell Lysis and Modulate NK Cell Function\nthrough Shared and Distinct Pathways","volume":"23","author":"Nguyen","year":"2025","journal-title":"Mol. Cancer\nRes."},{"issue":"1","key":"2026090707082841500_cit8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13046-025-03375-x","article-title":"Natural killer\ncells:\nthe immune frontline against circulating tumor cells","volume":"44","author":"Masmoudi","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"2026090707082841500_cit9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.clim.2008.08.012","article-title":"Functional impairment in circulating and intrahepatic\nNK cells and relative mechanism in hepatocellular carcinoma patients","volume":"129","author":"Cai","year":"2008","journal-title":"Clin Immunol"},{"key":"2026090707082841500_cit10","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3389\/fimmu.2019.00877","article-title":"Endometrial\nTumor Microenvironment Alters Human NK Cell Recruitment, and Resident\nNK Cell Phenotype and Function","volume":"10","author":"Degos","year":"2019","journal-title":"Front. Immunol."},{"issue":"10","key":"2026090707082841500_cit11","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.4049\/jimmunol.1202693","article-title":"Neuroblastoma-derived\nTGF-\u03b21 modulates the chemokine receptor repertoire of human\nresting NK cells","volume":"190","author":"Castriconi","year":"2013","journal-title":"J. Immunol."},{"key":"2026090707082841500_cit12","doi-asserted-by":"publisher","first-page":"1574742","DOI":"10.3389\/fimmu.2025.1574742","article-title":"CAR-NK cell\ntherapy: promise and challenges in solid tumors","volume":"16","author":"Balkhi","year":"2025","journal-title":"Front. Immunol."},{"issue":"6","key":"2026090707082841500_cit13","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/hep.26577","article-title":"Molecular profiling of stroma identifies osteopontin\nas an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma","volume":"58","author":"Sulpice","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"2026090707082841500_cit14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of Four Immune Subtypes Characterized\nby Distinct Composition and Functions of Tumor Microenvironment in\nIntrahepatic Cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"2026090707082841500_cit15","doi-asserted-by":"publisher","first-page":"1588538","DOI":"10.1080\/20013078.2019.1588538","article-title":"Extracellular\nvesicles derived from\nnatural killer cells use multiple cytotoxic proteins and killing mechanisms\nto target cancer cells","volume":"8","author":"Wu","year":"2019","journal-title":"J. Extracell. Vesicles"},{"key":"2026090707082841500_cit16","doi-asserted-by":"publisher","first-page":"658698","DOI":"10.3389\/fimmu.2021.658698","article-title":"Natural Killer\nCell-Derived Extracellular Vesicles: Novel Players in Cancer Immunotherapy","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"2026090707082841500_cit17","doi-asserted-by":"publisher","first-page":"698639","DOI":"10.3389\/fcell.2021.698639","article-title":"Extracellular\nVesicles From the Human Natural Killer\nCell Line NK3.3 Have Broad and Potent Anti-Tumor Activity","volume":"9","author":"Cochran","year":"2021","journal-title":"Front Cell Dev Biol."},{"issue":"9","key":"2026090707082841500_cit18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s12032-025-02965-1","article-title":"NK-derived\nexosomes in anti-tumor strategies","volume":"42","author":"Zhang","year":"2025","journal-title":"Med. Oncol."},{"issue":"4","key":"2026090707082841500_cit19","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.3390\/ijms24044026","article-title":"Natural\nKiller Cell-Derived Extracellular Vesicles as a Promising Immunotherapeutic\nStrategy for Cancer: A Systematic Review","volume":"24","author":"Chan","year":"2023","journal-title":"Int.\nJ. Mol. Sci."},{"issue":"8","key":"2026090707082841500_cit20","doi-asserted-by":"publisher","DOI":"10.1002\/jex2.70080","article-title":"Surface-Engineered\nNatural Killer Cell-Derived Small Extracellular Vesicles Induce Potent\nAnti-Tumour Effects in Lung Cancer Cells","volume":"4","author":"Kang","year":"2025","journal-title":"J.\nExtracell. Biol."},{"issue":"8","key":"2026090707082841500_cit21","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1016\/j.ymthe.2024.06.006","article-title":"Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy","volume":"32","author":"Gondaliya","year":"2024","journal-title":"Mol. Ther."},{"issue":"9","key":"2026090707082841500_cit22","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100025R","article-title":"Built-in\u2033 PD1 blocker to rescue NK-92 activity\nfrom PD-L1-mediated tumor escape mechanisms","volume":"35","author":"Mensali","year":"2021","journal-title":"FASEB J."},{"issue":"10","key":"2026090707082841500_cit23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139809","article-title":"Contrasting\nEffects of the Cytotoxic Anticancer\nDrug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib\non NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in\nNon-Small-Cell Lung Cancer Cells","volume":"10","author":"Okita","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"2026090707082841500_cit24","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1007\/s00262-023-03562-9","article-title":"Statins abrogate\ngemcitabine-induced PD-L1 expression\nin pancreatic cancer-associated fibroblasts and cancer cells with\nimproved therapeutic outcome","volume":"72","author":"Minz","year":"2023","journal-title":"Cancer Immunol.,\nImmunother."},{"key":"2026090707082841500_cit25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biomaterials.2018.10.034","article-title":"Enhancement of antitumor\npotency of extracellular vesicles\nderived from natural killer cells by IL-15 priming","volume":"190\u2013191","author":"Zhu","year":"2019","journal-title":"Biomaterials"},{"issue":"10","key":"2026090707082841500_cit26","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.3390\/cancers11101560","article-title":"Cocktail Strategy\nBased on NK Cell-Derived Exosomes and Their Biomimetic Nanoparticles\nfor Dual Tumor Therapy","volume":"11","author":"Wang","year":"2019","journal-title":"Cancers"},{"issue":"6","key":"2026090707082841500_cit27","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1158\/0008-5472.CAN-18-0779","article-title":"Natural Killer-Derived\nExosomal miR-186 Inhibits Neuroblastoma Growth and Immune Escape Mechanisms","volume":"79","author":"Neviani","year":"2019","journal-title":"Cancer Res."},{"issue":"2","key":"2026090707082841500_cit28","doi-asserted-by":"publisher","first-page":"102545","DOI":"10.1016\/j.xcrm.2025.102545","article-title":"Programmable iPSC-derived CAR-NK vesicles remodel the\nimmune microenvironment\nand eradicate tumors","volume":"7","author":"Zhang","year":"2026","journal-title":"Cell Rep. Med."},{"issue":"13","key":"2026090707082841500_cit29","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202521623","article-title":"Engineered\nCAR-NKT Extracellular Vesicles Suppress Tumor Progression and Enhance\nAntitumor Immunity","volume":"13","author":"Hao","year":"2026","journal-title":"Adv. Sci."},{"issue":"7","key":"2026090707082841500_cit30","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A\nmAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by\nUnleashing Both T and NK Cells","volume":"175","author":"Andre\u0301","year":"2018","journal-title":"Cell"},{"issue":"3","key":"2026090707082841500_cit31","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3892\/or.2021.7943","article-title":"CD155\/TIGIT,\na novel immune checkpoint in human cancers (Review)","volume":"45","author":"Liu","year":"2021","journal-title":"Oncol. Rep."},{"issue":"7","key":"2026090707082841500_cit32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion\nand elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat.\nImmunol."},{"issue":"21","key":"2026090707082841500_cit33","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-16-0933","article-title":"Molecular\nPathways: Targeting CD96 and TIGIT for Cancer Immunotherapy","volume":"22","author":"Blake","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"2026090707082841500_cit34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3389\/fimmu.2020.00331","article-title":"Low-Dose Gemcitabine\nTreatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor\nImmunity in Lung Cancer","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"2026090707082841500_cit35","doi-asserted-by":"publisher","first-page":"1981049","DOI":"10.1080\/2162402X.2021.1981049","article-title":"CD34(+) progenitor-derived NK cell and gemcitabine\ncombination therapy increases killing of ovarian cancer cells in NOD\/SCID\/IL2Rg(null)\nmice","volume":"10","author":"Van der Meer","year":"2021","journal-title":"OncoImmunology"},{"issue":"1","key":"2026090707082841500_cit36","doi-asserted-by":"publisher","first-page":"7656","DOI":"10.1038\/s41598-023-34827-z","article-title":"Combinatorial immunotherapy with\ngemcitabine and ex vivo-expanded NK cells induces anti-tumor effects\nin pancreatic cancer","volume":"13","author":"Koh","year":"2023","journal-title":"Sci. Rep"},{"issue":"17","key":"2026090707082841500_cit37","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.3390\/cancers14174229","article-title":"Safety and Efficacy\nof Allogeneic Natural Killer\nCells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory\nBiliary Tract Cancer: A Multicenter Open-Label Phase 1\/2a Trial","volume":"14","author":"Leem","year":"2022","journal-title":"Cancers"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00219","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4540\/66679878\/acs.molpharmaceut.6c00219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4540\/66679878\/acs.molpharmaceut.6c00219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:16:06Z","timestamp":1788779766000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/9\/4540\/5264198\/Engineered-Natural-Killer-Cell-Derived"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,17]]},"published-print":{"date-parts":[[2026,9,7]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00219","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}